| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2a data readout example | [212Pb]VMT-α-NET unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors | Phase 1/2a | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | |
Phase 1/2a data readout example | [212Pb]VMT-α-NET unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors | Phase 1/2a | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | |
Phase 1/2a data readout example | [212Pb]VMT-α-NET unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors | Phase 1/2a | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology |
Recent Updates
Recently added Catalysts
Perspective Therapeutics, Inc.$3.01
-0.16 (-5.05%)
D 37Pipeline Score Overvalued Biotech · Clinical
Market Cap
453.90 M
EPS
-1.40
P/E Ratio
-
Value Trade
3.51 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
21.37 M
Operating CF
-31.47 M
Total Assets
410.77 M
Total Liabilities
63.33 M
Equity
347.44 M
D/E Ratio
12,345
3.38 %
Week
-14.04 %
1 Month
-26.3 %
3 Month
87.74 %
6 Month
-50.25 %
5 Year
-99.47 %
All Time
Cash Data
Cash Position
270.93 M
Monthly Burn
10.49 M
Runway
23.8 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
2.81 M
52 Week Range
1.96 - 6.16
% held by Insiders
20.92 %
% held by Institutions
72.54 %
Enterprise Value
187.21 M
Total Shares
114.10 M
Short %
24 %
Float Shares
94.70 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Perspective Therapeutics, Inc.
383Total events
8Upcoming
59Tier-1 (high impact)
2006 – 2026Coverage
Upcoming catalysts 8
Q4 2026
T3Enrollment Milestone
By late 2026, 10 patients treated since Sep 2025 expected to have at least 24 weeks follow-up
Q4 2026
T3Enrollment Milestone
By late 2026, treated patients expected to have at least 32 weeks follow-up
Nov 2026
T2Oral Presentation
Plan to submit relevant updates on patients dosed to date for presentation in next 12 months
Event history 375
Jun 3, 2026
▲First Patient DosedVMT-α-NETTrial
First patient dosed in meningioma cohort of Phase 1/2a study
meningiomasource ↗
Jun 1, 2026
◆Oral PresentationVMT-α-NETPresentation
ASCO 2026 data analysis for VMT- -NET
SSTR2+ Neuroendocrine Tumorssource ↗
Jun 1, 2026
Jun 1, 2026
◆Oral PresentationPSV-359Presentation
Ongoing Phase 1/2a trial for PSV359
Advanced Solid Tumorssource ↗
Jun 2026
◆Quarterly UpdateCorporate
Cash balance of ~$267.8mm expected to provide funding into mid 2026
May 31, 2026
◆Oral PresentationVMT01Presentation
ASCO 2026 poster presentation of updated Phase 1/2a data for [212Pb]VMT01
melanomasource ↗
May 30, 2026
◆Oral PresentationVMT-α-NETPresentation
ASCO 2026 poster presentation of updated Phase 1/2a data for [212Pb]VMT-α-NET
neuroendocrine tumorssource ↗
May 29, 2026
◆Oral PresentationPSV-359Presentation
ASCO 2026 publication-only presentation of Phase 1/2a data for [212Pb]PSV359
solid tumorssource ↗
May 11, 2026
▲Enrollment UpdateVMT-α-NETTrial
Proof-of-concept cohort of meningioma patients opened
meningiomasource ↗
May 11, 2026
May 2026
◆Interim AnalysisVMT-α-NETTrial
Interim analysis reported at ASCO 2026 with data cut-off April 17, 2026
SSTR2-positive tumorssource ↗
Drug Pipeline Intelligence
D37
Pipeline Score $108M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.2x
rNPV / MCap Top 51%
Micro Cap (rank 448 of 912)
Percentile RankPerspective Therapeutics, Inc. faces pipeline headwinds (37/100), with $477M risk-adjusted pipeline value, led by VMT-α-NET in Neuroendocrine Tumors Unresectable (Phase 1), across $72B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VMT-α-NET Small molecule | Neuroendocrine Tumors | Phase 1 | NCT06148636 | 10% | $318M | ACTIVE NOT_RECRUITING | 24 | - | - | Dec 31, 2027 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
[212Pb]VMT01 Fast Track | melanoma | Phase 1/2a | 2026-05-22 | two confirmed responses out of seven (29%) treated; six patients (86%) experienced stable disease or partial response Read More | Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma • One new responder observed in the [ 212 Pb]VMT01 3.0 mCi mono Read More | |
[212Pb]VMT01 Fast Track | melanoma | Phase 1/2a | 2026-05-22 | two confirmed responses out of seven (29%) treated; six patients (86%) experienced stable disease or partial response Read More | Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma • One new responder observed in the [ 212 Pb]VMT01 3.0 mCi mono Read More | |
[212Pb]VMT01 Fast Track | melanoma | Phase 1/2a | 2026-05-22 | two confirmed responses out of seven (29%) treated; six patients (86%) experienced stable disease or partial response Read More | Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma • One new responder observed in the [ 212 Pb]VMT01 3.0 mCi mono Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CATX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CATX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CATXPerspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
Perspective Therapeutics has initiated a Phase 1/2a study for [212Pb]VMT-α-NET, dosing the first patient in the meningioma cohort. This study aims to assess the safety and efficacy of the therapy for meningiomas, which are prevalent brain tumors. The expansion reflects the company's strategy to explore treatment for various SSTR2-expressing tumors beyond neuroendocrine tumors.
Read more →CATX▼ -7.1%on this news· ran to -18% by day 3shared move
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Engineering the Alpha Advantage in Targeted Oncology Unlocking New Treatment Options Across Solid Tumors: Optimizing the Entire System Rapidly Advan
CATX is making strides in oncology with its next-generation radiopharmaceuticals targeting solid tumors. The ongoing Phase 1/2a trials for treatments like VMT- -NET and PSV359 demonstrate promising anti-tumor activities and a favorable safety profile. The company is optimizing its supply chain to ensure regional manufacturing and a steady production of ready-to-administer products. Their strategic focus on addressing unmet needs in the SSTR2+ neuroendocrine tumor market reinforces their commitment to innovative cancer therapies.
Read more →CATXPerspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma • One new responder observed in the [ 212 Pb]VMT01 3.0 mCi mono
Perspective Therapeutics announced updates on its clinical programs to be presented at the 2026 ASCO Annual Meeting. Their findings include two confirmed responses from the [212Pb]VMT01 monotherapy cohort, and the advancement of [212Pb]PSV359 to Cohort 3 with good safety profiles. The data demonstrated positive outcomes in heavily pre-treated melanoma patients, with no reported dose limiting toxicities across programs. Further detailed results are expected by late 2026.
Read more →CATXPerspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results • Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient conve
Perspective Therapeutics reported significant progress in their clinical programs and financial position for the first quarter of 2026. The company is advancing three clinical-stage oncology programs targeting various tumor types, with multiple catalysts expected later in the year. Their regional manufacturing network aims to enhance the supply chain for their radiopharmaceuticals. Despite a net loss this quarter, they maintain a substantial cash runway that supports ambitious clinical and operational plans into late 2027.
Read more →CATXAgenda Engineering the Alpha Advantage in Targeted Oncology Optimizing the Entire System Expanding the Addressable Market Unlocking New Treatment Options Across Solid Tumors: Choosing The Right Isotope Optimizing Structu
The article discusses advancements in targeted oncology with a focus on using 212Pb in theranostic approaches. It emphasizes expanding market potential through regional manufacturing and direct-to-hospital delivery of radiopharmaceuticals. Ongoing Phase 1/2a studies suggest promising results for the therapy VMT- -NET in treating neuroendocrine tumors. The article also notes potential side effects and the importance of robust supply chain configurations to meet treatment demands.
Read more →CATX▲ +8.3%on this news
Percent change in sum of diameters from baseline 0 1 2 3 4 5 0 8 16 24 32 40 48 56 64 72 80 88 96 Study Week Creatinine (mg/dL) Safety Analysis Set Somatosta
The article presents an update on the Phase I/IIa clinical trial for [212Pb]VMT- -NET, an alpha therapy aimed at treating SSTR2-expressing neuroendocrine tumors (NETs). As of the data cutoff on March 4, 2026, the therapy was reported to be well-tolerated with no dose-limiting toxicities. Efficacy was demonstrated through significant tumor shrinkage in some patients, although there were instances of increased blood creatinine levels and a couple of fatalities due to disease progression. Ongoing follow-up and treatment for patients in Cohorts 2 and 3 is expected to yield further results.
Read more →CATX▲ +6%on this news
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
The article discusses advancements in next-generation radiopharmaceuticals, highlighting a proprietary radioligand platform and a unique Pb-based chelator designed for safer broader use. The VMT-01 and PSV359 therapies show promising preliminary anti-tumor activity in ongoing clinical trials targeting melanoma and solid tumors, respectively. The company's strong intellectual property portfolio supports its innovative products, with important Phase 1/2 data expected by 2026. However, some treatment emergent adverse events were noted, marking an important area for continued monitoring.
Read more →CATXPerspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results • Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile wit
Perspective Therapeutics provided an update on its business and reported results for the year ending December 31, 2025. The lead program, VMT-α-NET, demonstrated a favorable tolerability profile and durable disease control in neuroendocrine tumors. All three clinical programs expect to present updates at medical conferences throughout 2026. The financial outlook remains positive with sufficient funding for ongoing clinical trials until late 2027.
Read more →CATX▲ +33.5%on this news
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants SEATTLE –
Perspective Therapeutics, Inc. has successfully priced an underwritten offering of $175 million, involving the sale of approximately 39.6 million shares of common stock and pre-funded warrants. The offering is expected to close soon, pending customary closing conditions. The net proceeds will be utilized to support ongoing clinical developments, augment manufacturing capabilities, and for general corporate purposes. This financing has received backing from leading healthcare investors, showcasing their confidence in the company's future. The offering aligns with the company's strategy to enhance its innovative cancer treatment technologies.
Read more →CATXPerspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference • Continued strong patient recruitment in neuroendocrine tumors fo
Perspective Therapeutics provided key updates on its clinical programs and strategic priorities ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference. The company reported robust patient recruitment for its neuroendocrine tumor program, VMT--NET, alongside promising safety and efficacy results. Clinical updates for other programs, including melanoma and FAP-targeting therapies, are expected in mid to late 2026. CEO Thijs Spoor emphasized ongoing investments to enhance product and process innovation, positioning Perspective as a leader in the radiopharmaceutical sector.
Read more →CATXPerspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium • Updated interim results with an addit
Perspective Therapeutics presented updated interim results from its Phase 1/2a trial of [212Pb]VMT-α-NET for neuroendocrine tumors at the 2026 ASCO GI Symposium. The latest analysis showed positive outcomes, with a 39% objective response rate and no adverse dose limiting toxicities reported. Overall, the results suggest both a favorable safety profile and significant anti-tumor activity. Moving forward, the company plans further patient enrollment and regulatory consultations in 2026.
Read more →CATX▼ -6.8%on this news
Corporate Presentation Developing the next generation of targeted therapies Higher potency payloads with cancer-specific targeting Upcoming data milestones Radiopharmaceutical therapy poised to revolutionize oncology tre
Perspective has outlined promising developments in targeted therapies, particularly in radiopharmaceutical treatments for various cancers. Their platform aims to enhance treatment efficacy while maintaining a favorable safety profile. Upcoming data milestones are expected to shed light on the effectiveness of treatments for neuroendocrine tumors and melanoma. Despite some reported adverse events, the overall findings suggest a robust potential for these therapies to revolutionize oncology.
Read more →CATXPerspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results • Updated interim results from the Company's [ 212 Pb]VMT-α-NET Phase 1/2a study supporting the therapy's compelling o
Perspective Therapeutics, Inc. (CATX) has recently reported their 3Q 2025 results and business highlights, showcasing updated interim findings from their Phase 1/2a clinical study of the radiopharmaceutical [212Pb]VMT-α-NET. The study's results, presented at several prominent medical conferences, indicate a favorable safety profile and promising anti-tumor activity among participants. Additionally, the company highlighted strong patient recruitment and a robust financial position, with $174 million in cash expected to support their ongoing clinical trials and operational investments through late 2026. Future updates and additional data from ongoing studies are anticipated in the coming months as the company aims to further validate its therapeutic innovations in cancer treatment.
Read more →CATXCorporate Presentation November 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this
The corporate presentation for CATX outlines the company's forward-looking clinical development plans, focusing on targeted cancer therapies. It emphasizes the potential market opportunities for its product candidates and the expected milestones through 2026. However, the company also acknowledges various risks, including regulatory approval delays and uncertainties related to clinical trial results. The presentation showcases an innovative pipeline aimed at enhancing cancer treatment efficacy.
Read more →CATX▼ -29%on this news
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025 • Updated interim results with an additional ~19 weeks of follo
Perspective Therapeutics presented updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT- -NET for treating neuroendocrine tumors at ESMO Congress 2025. The data revealed a 44% objective response rate in cohort 2 and demonstrated strong tolerability with no serious adverse events. Notably, 14 of the 16 patients in cohort 2 remained progression-free after a median follow-up of 41 weeks. Initial efficacy data for additional patients is anticipated in 2026.
Read more →CATXCorporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective's pipe
Perspective is advancing a Radiopharmaceutical Therapy (RPT) platform designed to offer targeted treatments for various tumors, particularly neuroendocrine tumors and metastatic melanoma. Their innovative approach includes a proprietary chelator for lead-based RPTs and a trial structure showing sustained anti-tumor activity with good tolerability. By optimizing the therapeutic window and ensuring efficient supply chain management, Perspective aims to enhance the delivery of oncology treatments. The positive early trial results highlight the potential of Perspective's pipeline to revolutionize cancer treatment.
Read more →CATXPerspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer Distinguished career as a Wall Street analyst and significant CFO experience, bringing keen insights and understanding of finance a
Perspective Therapeutics has appointed Joel Sendek as Chief Financial Officer, effective immediately. Mr. Sendek brings a wealth of experience in biotech finance and equity research, having previously served as CFO for several biotech companies. His extensive background is expected to support the company's ongoing clinical programs and position it as a leader in targeted alpha radiopharmaceuticals. The appointment follows the departure of previous CFO Juan Graham, who is credited for his contributions to the company.
Read more →CATXPerspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors SEATTLE –
Perspective Therapeutics has appointed Maya Martinez-Davis as an independent director to its Board, effective immediately. Martinez-Davis is currently President of GSK's U.S. Commercial business and has a significant background in oncology and biopharma, having served in key roles at Merck and Pfizer. Her experience is expected to complement the existing directors and management, bolstering the company’s mission to advance its clinical programs and improve cancer treatment outcomes. The company is at a critical juncture in developing its innovative radiopharmaceutical treatments.
Read more →CATXPerspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results • [ 212 Pb]VMT-α-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a P
Perspective Therapeutics announced business highlights and detailed the results for Q2 2025, particularly regarding the [212Pb]VMT-α-NET study. The company reported promising interim results showing objective responses in patients. Additionally, they highlighted a favorable safety profile and strong cash reserves to support ongoing and future clinical trials. The recent scientific updates underline their commitment to developing new treatment options for cancer patients.
Read more →CATX▲ +8.6%on this news
Corporate Presentation July 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this pres
The Corporate Presentation for CATX outlines the company's future plans, including the development of targeted therapies and multiple clinical-stage programs aimed at improving cancer treatment. The presentation highlights various aspects of the company's operations such as regulatory communications, manufacturing capabilities, and innovative technologies. However, it also emphasizes risks and uncertainties inherent in the clinical trial and regulatory approval processes. Overall, CATX aims to significantly expand its impact on oncology treatment with its robust pipeline of programs and strategic planning.
Read more →CATX▲ +18.8%on this news
Perspective Therapeutics Commences Recruitment for [ 212 Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial • [ 212 Pb]VMT‑α‑NET Phase 1/2a study is
Perspective Therapeutics has initiated recruitment for the third dose escalation cohort of its Phase 1/2a clinical trial for [212Pb]VMT-α-NET, targeting patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors. This new cohort will test a higher fixed dose, previously studied in Cohort 2, based on positive safety and efficacy signals. The company is also gearing up for further clinical updates in late 2025, focusing on treatment follow-up and dosimetry analysis. The trial's design includes monitoring for dose limiting toxicities to ensure patient safety.
Read more →CATX▼ -7%on this news· ran to +21% by day 3shared move
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting • Updated interim results with an additional ~16 weeks
Perspective Therapeutics presented updated interim data from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting. The data showed a favorable safety profile with no dose-limiting toxicities, and substantial disease control in patients, with many remaining free from progression. Four out of seven patients in Cohort 2 experienced objective responses, with several responses pending confirmation. The trial remains part of an effort to establish [212Pb]VMT-α-NET as a promising treatment for neuroendocrine tumors.
Read more →CATX▲ +6.8%on this news
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results • First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Onco
Perspective Therapeutics, Inc. has provided a business update and reported its financial results for Q1 2025. The company highlighted upcoming clinical presentations at the American Society of Clinical Oncology Annual Meeting, along with ongoing recruitment in various clinical trials for its new medicines targeting neuroendocrine tumors and melanoma. It also noted robust financial health, expecting its funds to sustain planned clinical milestones through late 2026. Overall progress in patient recruitment and safety monitoring indicates a positive trajectory for the company’s innovative therapies.
Read more →CATXPerspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors SEATTLE –
Perspective Therapeutics has announced the dosing of the first patient with their investigational radiopharmaceutical [212Pb]PSV359 in a Phase 1/2a trial focusing on patients with FAP- positive solid tumors. The trial aims to ascertain the safety and preliminary anti-tumor activity of PSV359. This treatment targets tumors characterized by fibroblast activation protein, which holds significance in cancer therapy. Perspective's innovative approach could pave the way for enhanced outcomes in cancer treatment, especially in cases inadequately addressed by existing therapies.
Read more →CATXPerspective Therapeutics Announces First Patient Dosed with [ 212 Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma SEATTLE –
Perspective Therapeutics has announced the first patient dosed with [212Pb]VMT01 in a Phase 1/2a trial for metastatic melanoma. This study aims to evaluate the safety of this targeted alpha-particle therapy as monotherapy. The FDA has granted Fast Track Designation for the treatment, highlighting its potential in addressing unmet medical needs in this patient population. The trial also includes patients whose melanoma has metastasized to the brain, allowing for a comprehensive understanding of the therapy's effects. Initial results from earlier cohorts have been encouraging, paving the way for this new cohort's exploration.
Read more →CATX▼ -8.1%on this news
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results • On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical progr
Perspective Therapeutics has announced significant progress in its clinical programs, with multiple updates expected through mid-2026. The company has achieved first-in-human dosing of a PD-1 inhibitor in combination with VMT01 and has cleared an investigational new drug application for PSV359 targeting solid tumors. Enrollment for their next-generation medicine VMT- -NET is ongoing, with 30 patients enrolled as of February 2025. Despite achievements, the company remains dependent on ongoing FDA consultations for next steps in their trials.
Read more →CATXPerspective Therapeutics Announces First Patient Dosed with [ 212 Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma SEATTLE –
Perspective Therapeutics announced the dosing of the first patient with [212Pb]VMT01, in combination with nivolumab, in a Phase 1/2a study targeting MC1R-positive metastatic melanoma. Initial cohorts indicated a promising safety profile and early anti-tumor activity. The FDA has granted Fast Track Designation for [212Pb]VMT01, aimed at addressing significant unmet medical needs in melanoma treatment. The study seeks to optimize low-dose radiopharmaceuticals in combination with immunotherapy for improved patient outcomes.
Read more →CATXCorporate Presentation Developing the Next Generation of Targeted Therapies Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective's pipeline and platform has the potential to significantly ex
Perspective is advancing its innovative radiopharmaceutical therapy that targets various tumors, significantly broadening its applicability. The company has developed a proprietary chelator optimized for lead-based RPTs, which enhances treatment efficacy. Initial trials, particularly for neuroendocrine tumors, have shown sustained anti-tumor activity and good tolerance without renal function decline. Their melanoma program also demonstrates promise with ongoing Phase 1/2a trials.
Read more →CATX▼ -7%on this news
Corporate Presentation February 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this
CATX's February 2025 corporate presentation outlines forward-looking statements related to its clinical development plans, regulatory communications, and market opportunities for its product candidates. The company emphasizes its innovative platform technology aimed at improving cancer treatment through targeted therapies and intends to enhance the care of patients with various cancers. However, significant risks and uncertainties regarding regulatory approvals and clinical trial progression remain, which could affect the company's future outcomes.
Read more →CATX▲ +10.5%on this news
Perspective Therapeutics Continues to Pursue Dose Escalation of [ 212 Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposiu
Perspective Therapeutics is advancing its Phase 1/2a clinical trial of [212Pb]VMT-α-NET, presenting updated interim results at the 2025 ASCO Gastrointestinal Cancers Symposium. The study shows a favorable safety profile with no observed dose-limiting toxicities, while three patients in Cohort 2 demonstrated objective responses to the treatment. The drug shows potential in reducing tumor activity in patients with unresectable or metastatic neuroendocrine tumors. The company plans to proceed with dose escalation in consultation with the FDA, having received Fast Track Designation for this treatment approach.
Read more →CATXPerspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer SEATTLE, WASHINGTON –
Perspective Therapeutics, Inc. announced the appointment of Juan Graham as Chief Financial Officer, effective January 6, 2025. This leadership change comes as the company prepares to propel its growth and advance multiple clinical programs. Perspective has recently provided initial clinical data for two potential medicines and aims to develop additional programs, reinforcing the company’s commitment to cancer treatment. With nearly 25 years of experience in the life sciences, Graham's financial expertise is expected to enhance the company's financial strategy.
Read more →CATXPerspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference • Anticipates multiple clinical updates in the next 12-18 months,
Perspective Therapeutics has announced strategic priorities and updates ahead of the upcoming J.P. Morgan Healthcare Conference. The company expects multiple clinical updates in the next 12-18 months, including ongoing progress in clinical trials and plans for new asset developments. With a healthy cash position of approximately $227.8 million, Perspective is well-positioned to fund its planned operations and capital investments into late 2026. The presentation at the conference is set for January 15, 2025.
Read more →CATX▼ -7.3%on this news
Corporate Presentation December 2024 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this
Perspective Therapeutics has provided its corporate presentation detailing forward-looking statements regarding its clinical development plans and expected timeframes. The company highlights a robust pipeline aimed at developing targeted alpha particle therapies for cancer treatment, showcasing its financial stability with around $267.8 million available to fund operations into mid-2026. However, the presentation cautions about potential regulatory and operational risks that could impact their development plans and timelines.
Read more →CATX▼ -51.4%on this news
Perspective Therapeutics to Pursue Dose Escalation of [ 212 Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidiscip
Perspective Therapeutics, Inc. has announced plans to escalate the dosage of its investigational therapy [212Pb]VMT- -NET in an ongoing Phase 1/2a clinical trial. Presented findings indicate that the therapy demonstrated a favorable safety profile, with eight out of nine patients achieving durable control of their condition and some experiencing measurable tumor reduction. The decisions for dosage escalation are being made in compliance with Safety Monitoring Committee recommendations, and the company will continue to engage with the FDA on the next steps for this promising treatment. The trial is aimed at patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors.
Read more →CATX▼ -11.7%on this news· ran to -31% by day 3
Corporate Presentation November 2024 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this
The article presents a corporate overview of CATX, highlighting its forward-looking statements and expectations regarding clinical development, regulatory approvals, and market opportunities. CATX is advancing multiple clinical-stage programs and anticipates significant milestones through 2025. With a current cash balance of approximately $267.8 million, the company aims to support its development efforts. However, there are inherent risks concerning the regulatory landscape, clinical trial uncertainties, and financial stability.
Read more →CATXPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results • Advancing investigation of [ 212 Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivoluma
Perspective Therapeutics, Inc. reported successful advancements in their drug candidate [212Pb]VMT01 for treating metastatic melanoma and neuroendocrine tumors during their fiscal 3Q 2024 update. The company highlighted ongoing Phase 1/2a trials, recent FDA Fast Track Designation, and a solid financial position with approximately $268 million available to support future operations. Initial results showed both efficacy and safety, but also noted instances of patient mortality and limited responses which warrant further investigation. The organization is positioned to move multiple pre-IND assets into clinical stages in the coming months.
Read more →CATXPerspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [ 212 Pb]VMT01 Based on Data Presented at the 21 st International Congress of the Society for Melanoma Research [
Perspective Therapeutics announced encouraging outcomes from its Phase 1/2a study of [212Pb]VMT01, a radiopharmaceutical therapy targeting metastatic melanoma. These results were presented at the 21st International Congress of the Society for Melanoma Research. The therapy demonstrated efficacy without renal toxicities, leading to FDA's Fast Track Designation. Further studies are planned to explore lower dosages and combination therapies.
Read more →CATXPerspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma SEATTLE –
Perspective Therapeutics has received Fast Track Designation from the FDA for VMT01, aimed at diagnosing and treating patients with MC1R-positive metastatic melanoma. This designation allows for expedited development, which is crucial given the significant unmet medical needs in this patient population. The company plans to enhance VMT01's clinical development and has recently completed a toxicity observation period in its Phase 1/2a study. With around 100,000 new melanoma cases annually in the U.S., this advancement is particularly timely.
Read more →CATX▲ +5.7%on this news
Corporate Presentation August 2024 NYSE: CATX Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements i
The corporate presentation for CATX outlines forward-looking statements regarding its clinical development plans, regulatory expectations, market opportunities, and financial outlook. The company emphasizes a strong financial position with $292.9 million in cash and equivalents, supporting its pipeline until mid-2026. CATX is advancing multiple clinical-stage programs in pan-cancer treatments and anticipates significant milestones through 2025, despite inherent risks related to regulatory approval processes and market competition.
Read more →CATXPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results • Completed enrollment of initial Cohort 2 patients in its VMT-α-NET and VMT01 clinical trials • On trac
Perspective Therapeutics, Inc. (CATX) reported its fiscal 2Q 2024 results, highlighting significant advancements in its clinical trials for VMT-α-NET and VMT01. The company completed enrollment of initial Cohort 2 patients and is on track to move multiple pre-IND assets into clinical stages within the next 12-18 months. With a solid cash balance of approximately $293 million, the company is positioned to fund its operations through mid-2026 while continuing to develop its manufacturing capabilities. The FDA also granted Fast Track Designation for its VMT-α-NET program, facilitating quicker development timelines for this promising therapeutic approach.
Read more →CATXPerspective Therapeutics Announces 1-for-10 Reverse Stock Split SEATTLE, WASHINGTON –
Perspective Therapeutics, Inc. has announced a 1-for-10 reverse stock split effective June 14, 2024. As a result, the number of outstanding shares will be reduced from approximately 674.3 million to about 67.4 million. The split follows stockholder approval from the annual meeting held on May 31, 2024, and is part of the company's strategies as it progresses in its clinical trials for cancer treatments. All outstanding options and warrants will be adjusted accordingly as well.
Read more →CATXPerspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants SEATTLE
Perspective Therapeutics, Inc. has announced the pricing of an underwritten offering of common stock, which aims to raise approximately $80 million. The offering includes 51,515,880 shares priced at $1.51 each, along with pre-funded warrants. The proceeds will support continued clinical development of various cancer therapies and the expansion of manufacturing facilities. The offering is expected to close on or about May 29, 2024, pending customary closing conditions.
Read more →CATXPerspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 SEATTLE, WASHINGTON –
Perspective Therapeutics, Inc. will present its research at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024 in Toronto. The presentations will focus on the company's ongoing studies, including the Phase 1/2a trial of [212Pb]VMT-NET for neuroendocrine tumors, and innovative targeted therapies such as [212Pb]VMT01 for melanoma. The CEO expressed optimism about their clinical and preclinical advancements, underscoring the commitment to improve care for patients with challenging tumors. This meeting will also feature joint presentations from independent investigators related to ongoing clinical trials.
Read more →CATX▼ -10.8%on this newsshared move
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results • Continued progress enrolling in its VMT-α-NET and VMT01 clinical trials • Disclosed a new internally d
Perspective Therapeutics, Inc. announced their fiscal Q1 2024 results, highlighting continued enrollment in their VMT-α-NET and VMT01 clinical trials. The company raised significant funds amounting to $177.2 million and $49.5 million under their ATM Agreement to support their projects. They disclosed a new molecule targeting fibroblast activation protein and received FDA Fast Track Designation for their [212Pb]VMT-α-NET clinical trial. Updates from ongoing studies are expected in the latter half of 2024.
Read more →CATXIsoRay Announces the Resignation of Chairman and CEO Thomas LaVoy; Industry Veteran Lori Woods Appointed Interim CEO; Mick McCormick Appointed Chairman of the Board
IsoRay Announces the Resignation of Chairman and CEO Thomas LaVoy; Industry Veteran Lori Woods Appointed Mick McCormick Appointed Chairman RICHLAND, Wash., June 5, 2018 - IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and
Read more →CATXIsoRay Announces Fourth Quarter Fiscal 2017 Revenue of $1.37 Million, 22% Fourth Quarter-over-Fourth Quarter Increase Gross Margin Expands to 36% on Continued Process Improvements and Expense Reduction
IsoRay Announces Fourth Quarter Fiscal 2017 Revenue of $1.37 Million, 22% Fourth Quarter-over-Fourth Quarter Increase Gross Margin Expands to 36% on Continued Process Improvements and Expense Reduction RICHLAND, Wash., September 28, 2017 -- IsoRay, Inc. (NYSE MKT: ISR), a me
Read more →CATXIsoRay Announces Appointment of Mark Austin as Controller, Principal Accounting and Financial Officer Public Accounting Background
Appointment of Mark Austin as Principal Accounting and Financial Officer RICHLAND, Wash., July 7, 2017 -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain,
Read more →CATXIsoRay Announces Third Quarter Fiscal 2017 Financial Results Revenue Increased 7% This Quarter over Third Quarter Last Year and 24% This Quarter over Prior Quarter
Third Quarter Fiscal 2017 Financial Results 7% This Quarter over Third Quarter Last Year and 24% This Quarter over Prior Quarter RICHLAND, Wash., May 10, 2017 -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioiso
Read more →CATXIsoRay Announces Final Court Approval of Class Action Settlement Settlement Fully Funded by D&O Insurance
Announces Final Court Approval of Class Action Settlement Fully Funded by D&O Insurance RICHLAND, Wash., March 9, 2017 -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of
Read more →CATXIsoRay Announces Second Quarter Fiscal 2017 Financial Results Management Continues to Expect Stronger Second Half of Fiscal 2017
Announces Second Quarter Fiscal 2017 Financial Results Continues to Expect Stronger Second Half of Fiscal 2017 RICHLAND, Wash., February 8, 2017 -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applicati
Read more →CATXIsoRay Announces First Quarter Fiscal 2017 Financial Results Management Continues to Expect Stronger Second Half of Fiscal 2017
Announces First Quarter Fiscal 2017 Financial Results Continues to Expect Stronger Second Half of Fiscal 2017 RICHLAND, Wash., November 8, 2016 -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applicatio
Read more →CATXIsoRay, Inc. Enters Into Agreement to Settle Class Action Shareholder Litigation Final Settlement Requires Court Approval
IsoRay, Inc. Enters Into Agreement to Settle Class Action Shareholder Litigation Final Settlement Requires Court Approval RICHLAND, Wash., September 27, 2016 - - IsoRay, Inc. ("IsoRay") (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and med
Read more →CATXIsoRay Announces Fourth Quarter and Year End Fiscal 2016 Financial Results Management Presenting at Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday
IsoRay Announces Fourth Quarter and Year End Fiscal 2016 Financial Results Management Presenting at Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016 at 10:00 am ET RICHLAND, Wash., September 8, 2016 IsoRay, Inc. (NYSE MKT: ISR), a medi
Read more →CATXIsoRay Announces Third Quarter Fiscal 2016 Financial Results and Early Conclusions from Ongoing Strategic Review Process
IsoRay Announces Third Quarter Fiscal 2016 Financial Results and Early Conclusions from Ongoing Strategic Review Process RICHLAND, Wash., May 10, 2016 IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applic
Read more →CATXISORAY REPORTS SECOND QUARTER FISCAL 2016 FINANCIAL RESULTS 12% Revenue Growth in The 2 nd Quarter 2016 Over 2 nd Quarter 2015 RICHLAND, Washington (
SECOND QUARTER FISCAL 2016 FINANCIAL RESULTS Growth in The 2nd Quarter 2016 Over 2nd Quarter 2015 RICHLAND, Washington (February 10, 2016) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications fo
Read more →CATXIsoRay Appoints Thomas LaVoy as CEO To Take Office on February 15 Richland, WA
IsoRay Appoints Thomas LaVoy as CEO To Take Office on February 15 Richland, WA-January 14, 2016 - IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, hea
Read more →CATXIsoRay Chairman and CEO Dwight Babcock to Retire; Tom LaVoy Elected New Chairman & Bill Cavanagh Appointed Interim CEO Richland, WA
IsoRay Chairman and CEO Dwight Babcock Tom LaVoy Elected New Chairman & Bill Cavanagh Appointed Interim CEO Richland, WA-January 7, 2016-IsoRay Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the tre
Read more →CATXFIRST QUARTER FISCAL 2016 FINANCIAL RESULTS
FIRST QUARTER FISCAL 2016 FINANCIAL RESULTS Growth In The 1st Quarter 2016 Over 1st Quarter 2015 RICHLAND, Washington (November 10, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for
Read more →CATXIsoRay, Inc. REPORTS 9% REVENUE INCREASE FOR FISCAL YEAR 2015 Spurred By 41% Revenue Growth In The 4 th Quarter Over Prior Year RICHLAND, Washington (
Inc. REPORTS 9% REVENUE INCREASE FOR FISCAL YEAR 2015 By 41% Revenue Growth In The 4th Quarter Over Prior Year RICHLAND, Washington (September 15, 2015) - IsoRay, Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medic
Read more →CATXAppointment of New Director
Appointment of New Director Former EVP of Global Sales and Marketing for Columbia Sportswear, Appointed to Board Richland, WA (June 22, 2015) - IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications,
Read more →CATXISORAY, INC. REPORTS THIRD QUARTER RESULTS Institutional Interest On The Rise Following Recently Published Reports Showing Cesium-131 ' s Success in Treating Cancer RICHLAND, Washington (
ISORAY, INC. REPORTS THIRD QUARTER RESULTS Institutional Interest On The Rise Following Recently Published Reports Cesium-131's Success in Treating Cancer RICHLAND, Washington (May 18, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed b
Read more →CATXISORAY, INC. REPORTS SECOND QUARTER RESULTS Published Reports Confirm Cesium-131 is a True Success in Treating Cancer RICHLAND, Washington (
ISORAY, INC. REPORTS SECOND QUARTER RESULTS Published Reports Confirm Cesium-131 is a True Success in Treating Cancer RICHLAND, Washington (February 18, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioiso
Read more →CATXISORAY, INC. REPORTS FIRST QUARTER RESULTS 7% Revenue Growth In Prostate Cancer Cases Quarter Over Quarter RICHLAND, Washington (
ISORAY, INC. REPORTS FIRST QUARTER RESULTS 7% Revenue Growth In Prostate Cancer Cases Quarter Over Quarter RICHLAND, Washington (November 17, 2014) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applic
Read more →CATXIsoRay, Inc. REPORTS FISCAL YEAR 2014 RESULTS Reports Growing List Of Major Accomplishments RICHLAND, Washington (
Inc. REPORTS FISCAL YEAR 2014 RESULTS Growing List Of Major Accomplishments RICHLAND, Washington (September 30, 2014) - IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced its financial res
Read more →CATXIsoRay, Inc. reports third QUARTER RESULTS Sales Continue To All Study Sites Beyond Planned Enrollment Levels As Data Matures For Presentation And Peer Review RICHLAND, Washington (
Inc. reports third QUARTER RESULTS Continue To All Study Sites Beyond Planned Enrollment Levels As Data Matures For Presentation And Peer Review Washington (May 16, 2014) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medi
Read more →CATXIsoRay, Inc. Prices Registered Direct Offering of Common Stock RICHLAND, WA
IsoRay, Inc. Prices Registered Direct Offering of Common RICHLAND, WA, March 21, 2014 (GLOBE NEWSWIRE) - IsoRay, Inc. (NYSE MKT:ISR) announced today that it has entered into definitive agreements with two institutional investors to sell 5,644,300 shares of common stock at a pr
Read more →CATXInc.
Inc. reports Second QUARTER RESULTS Revenue Growth 2013 Quarter Over 2012 Quarter Washington (February 18, 2014) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of cancer
Read more →CATXFDA CLEARS ISORAY'S LIQUID CESIUM (CESITREX) FOR USE WITH GLIASITE IN TREATING GLIOBLASTOMAS AND METASTATIC BRAIN CANCERS Richland, WA (
LIQUID CESIUM (CESITREX) FOR USE WITH GLIASITE IN TREATING GLIOBLASTOMAS AND METASTATIC BRAIN Richland, WA (January 7, 2014) - - IsoRay Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications
Read more →CATXIsoRay, Inc. reports FIRST QUARTER RESULTS 13% Revenue Growth In Brain, Lung and Other Non-Prostate Cancer Cases Quarter Over Quarter RICHLAND, Washington (
Inc. reports FIRST QUARTER RESULTS Revenue Growth In Brain, Lung and Other Non-Prostate Cancer Cases Quarter Over Quarter Washington (November 15, 2013) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope a
Read more →CATXIsoRay, Inc. REPORTS FISCAL YEAR 2013 RESULTS Non-Prostate Revenues Up To 17% of Total Revenues RICHLAND, Washington (
Inc. REPORTS FISCAL YEAR 2013 RESULTS Revenues Up To 17% of Total Revenues RICHLAND, Washington (September 30, 2013) - IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced its financial resu
Read more →CATXIsoRay, Inc. Contact: 350 Hills Street, Suite 106 Dwight Babcock Richland, WA 99354 Chairman & CEO www.isoray.com 509-375-1202 dbabcock@isoray.com FOR IMMEDIATE RELEASE IsoRay, Inc. Announces Underwritten Offering Richla
Contact: 350 Hills Street, Suite 106 Dwight Babcock Richland, WA 99354 Chairman & CEO www.isoray.com 509-375-1202 dbabcock@isoray.com Inc. Announces Underwritten Offering Richland, WA (August 28, 2013) - IsoRay, Inc. (NYSE MKT: ISR), specializing in the development, manufact
Read more →CATXIsoRay, Inc. reports Third QUARTER RESULTS 28% Increase in Third Quarter Revenues Over Second Quarter RICHLAND, Washington (
Inc. reports Third QUARTER RESULTS Increase in Third Quarter Revenues Over Second Quarter Washington (May 15, 2013) - IsoRay, Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer
Read more →CATXIsoRay, Inc. reports SECOND QUARTER RESULTS 14% Of Revenue Attributed To Non Prostate Cases Fueled By New Cancer Facilities RICHLAND, Washington (
Inc. reports SECOND QUARTER RESULTS Of Revenue Attributed To Non Prostate Cases Fueled By New Cancer Facilities Washington (February 14, 2013) - IsoRay, Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications fo
Read more →CATXIsoRay, Inc. reports FIRST QUARTER RESULTS Garnering New Cancer Treatment Revenues Remains The Strategy For Future Growth RICHLAND, Washington (
Inc. reports FIRST QUARTER RESULTS New Cancer Treatment Revenues Remains The Strategy For Future Growth Washington (November 14, 2012) - IsoRay, Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain
Read more →CATXIsoRay, Inc. REPORTS FISCAL YEAR 2012 RESULTS Non Prostate Revenues Up 75% To 14% of Total Revenues RICHLAND, Washington (
Inc. REPORTS FISCAL YEAR 2012 RESULTS Prostate Revenues Up 75% To 14% of Total Revenues RICHLAND, Washington (September 28, 2012) - IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced its f
Read more →CATXISORAY Announces Financing of $3.5 Million to Advance its GliaSite and New Emerging Cancer Solutions for Internal Radiation Therapy Richland, WA (
Financing of $3.5 Million to Advance its New Emerging Cancer Solutions for Internal Radiation Therapy Richland, WA (July 16, 2012) - - IsoRay, Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced t
Read more →CATXIsoRay, Inc. reports THIRD QUARTER RESULTS Significant Growth in Non-Prostate Sales Realized As Company Anticipates International Launch of GliaSite and Lung Cancer Mesh RICHLAND, Washington (
Inc. reports THIRD QUARTER RESULTS Growth in Non-Prostate Sales Realized As Company Anticipates Launch of GliaSite and Lung Cancer Mesh RICHLAND, Washington (May 15, 2012) - IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical
Read more →CATXSharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com IsoRay, Inc. reports PERFORMANCE FOR SECOND FISCAL QUARTER New Initiatives and Treatment Sites Expected to Stimul
FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com Inc. reports PERFORMANCE FOR SECOND FISCAL QUARTER Initiatives and Treatment Sites Expected to Stimulate Growth Washington (February 15, 2012) - IsoRay Inc. (AMEX: ISR), a medical te
Read more →CATXUnassociated Document FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com ISORAY, INC. REPORTS FIRST QUARTER RESULTS CITING GROWTH IN NEW CANCER TREATMENT REVENUES New Cancer Trea
FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com ISORAY, INC. REPORTS FIRST QUARTER RESULTS CITING GROWTH IN NEW CANCER TREATMENT REVENUES New Cancer Treatment Revenues and Launch of GliaSite Expected to Fuel Future Growth RICHLAN
Read more →CATXUnassociated Document FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 email: schultzpr@mchsi.com ISORAY ANNOUNCES MAJOR INTERNATIONAL DISTRIBUTION AGREEMENT FOR GLIASITE FDA-Cleared GliaSite Balloon Cat
FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 email: schultzpr@mchsi.com ISORAY ANNOUNCES MAJOR INTERNATIONAL DISTRIBUTION AGREEMENT FOR GLIASITE FDA-Cleared GliaSite Balloon Catheter System is World's Only Device to Deliver Liquid Radiation Source Th
Read more →CATXUnassociated Document FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 email: schultzpr@mchsi.com ISORAY Announces Financing for $2.3 Million to Advance its New Emerging Cancer Solutions for Brain, Lung
FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 email: schultzpr@mchsi.com ISORAY Announces Financing for $2.3 Million to Advance its New Emerging Cancer Solutions for Brain, Lung and Breast Cancer Richland, WA (October 13, 2011) - - IsoRay, Inc. (AMEX: ISR
Read more →CATXSharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com ISORAY, INC. REPORTS IMPROVED PERFORMANCE IN FISCAL YEAR 2011 New Products and Sales Initiated in FY2011 Final Quarter Expected
FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com ISORAY, INC. REPORTS IMPROVED PERFORMANCE IN FISCAL YEAR 2011 New Products and Sales Initiated in FY2011 Final Quarter Expected to Power Growth RICHLAND, Washington (September 28,
Read more →CATXUnassociated Document FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 email: schultzpr@mchsi.com ISORAY ACQUIRES EXCLUSIVE WORLDWIDE LICENSE FOR LIQUID IODINE IOTREX FOR GLIASITE BRAIN CANCER TREATMENT
FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 email: schultzpr@mchsi.com ISORAY ACQUIRES EXCLUSIVE WORLDWIDE LICENSE FOR LIQUID IODINE IOTREX FOR GLIASITE BRAIN CANCER TREATMENT August Launch Remains on Target for World's Only Device to Deliver Liquid Ra
Read more →CATXUnassociated Document FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com ISORAY, INC. REPORTS GAINS IN THIRD QUARTER FISCAL YEAR 2011 RESULTS 17% Revenue Increase Fuels Significa
FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com ISORAY, INC. REPORTS GAINS IN THIRD QUARTER FISCAL YEAR 2011 RESULTS 17% Revenue Increase Fuels Significant Financial Improvement RICHLAND, Washington (May 16, 2011) - IsoRay Inc.
Read more →CATXSharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com ISORAY, INC. ANNOUNCES SECOND QUARTER FISCAL YEAR 2011 RESULTS Reduced Cash Burn and Domestic and International Developments Po
FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com INC. ANNOUNCES SECOND QUARTER FISCAL YEAR 2011 RESULTS Cash Burn and Domestic and International Developments Points to Washington (February 15, 2011) - IsoRay Inc. (AMEX: ISR), anno
Read more →CATXSharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com ISORAY, INC. ANNOUNCES FINANCING COMMITMENT OF $4,325, 000 Funding to Fuel New Development and Accelerate Growth RICHLAND, Wash
FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 Email: schultzpr@mchsi.com INC. ANNOUNCES FINANCING COMMITMENT OF $4,325, 000 to Fuel New Development and Accelerate Growth Washington (November 22, 2010) - IsoRay Inc. (AMEX: ISR) has entered a securities pu
Read more →CATXUnassociated Document FOR IMMEDIATE RELEASE Contact: Dwight Babcock Tel: (520) 240-4840 Email: dbabcock@isoray.com ISORAY, INC. ANNOUNCES FIRST QUARTER FISCAL YEAR 2011 RESULTS Rising Adoption and New Developments Expect
FOR IMMEDIATE RELEASE Contact: Dwight Babcock Tel: (520) 240-4840 Email: dbabcock@isoray.com INC. ANNOUNCES FIRST QUARTER FISCAL YEAR 2011 RESULTS Adoption and New Developments Expected to Stimulate Sales and Spur Washington (November 16, 2010) - IsoRay Inc. (AMEX: ISR)
Read more →CATXUnassociated Document Contact: Dwight Babcock, CEO 520 240 4840 dbabcock@isoray.com ISORAY, INC. ANNOUNCES FISCAL YEAR 2010 RESULTS Expanding Applications and Diversification Expected to Fuel Growth and Sales RICHLAND, W
Contact: Dwight Babcock, CEO 520 240 4840 dbabcock@isoray.com ISORAY, INC. ANNOUNCES FISCAL YEAR 2010 Expanding Applications and Diversification Expected to Fuel Growth and Sales RICHLAND, Washington (September 28, 2010) - IsoRay Inc. (AMEX: ISR,) a medical isotope comp
Read more →CATXUnassociated Document FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 email: schultzpr@mchsi.com ISORAY AND HOLOGIC SIGN EXCLUSIVE WORLDWIDE LICENSE FOR CRUCIAL BRAIN CANCER TREATMENT DEVICE FDA-Cleared
FOR IMMEDIATE RELEASE Contact: Sharon Schultz Tel: (301) 351-0109 email: schultzpr@mchsi.com AND HOLOGIC SIGN EXCLUSIVE WORLDWIDE LICENSE FOR BRAIN CANCER TREATMENT DEVICE GliaSite Balloon Catheter Is World's Only Device Deliver Liquid Radiation Source Therapy WA (June 23,
Read more →CATXBrachytherapy: An Initial Report.
RELEASE for May 12, 2010 INC. REPORTS THIRD QUARTER RESULTS Washington - IsoRay Inc. (AMEX: ISR) a medical isotope company focusing on the treatment of prostate, lung, head and neck and other malignant disease through the use of its proprietary radioisotope technology, announ
Read more →CATXUnassociated Document
and REPLACING IsoRay, Inc. Reports Second Quarter Results WIRE)-- The first line of the table header should read: Three months ended December 31, (sted Six months ended December 31,). corrected release reads: ISORAY, INC. REPORTS SECOND QUARTER Inc. (AMEX:ISR) a medical isot
Read more →CATXUnassociated Document Press Releases NEWS RELEASE for
RELEASE for February 16, 2010 at 4:30PM EST Inc. Reports Second Quarter Results Washington - IsoRay Inc. (AMEX: ISR) a medical isotope company focusing on the treatment of prostate, lung, head and neck and other malignant disease through the use of its proprietary radioisotop
Read more →CATXFor Release
For Release: November 16, 2009 at 7:30AM EST Contact: Dwight Babcock, CEO 520 240 4840 dbabcock@isoray.com Inc. Reports First Quarter Results Washington - IsoRay Inc. (AMEX: ISR) a medical isotope company focusing on the treatment of prostate, lung, head and neck and other m
Read more →CATXUnassociated Document NEWS RELEASE for
NEWS RELEASE for September Contact: Dwight Babcock, CEO (520) 240-4840 dbabcock@isoray.com Inc. Announces Fiscal Year 2009 Results Washington (September 24, 2009) IsoRay Inc. (AMEX:ISR), a medical isotope company focused on the treatment of lung cancer, head and neck tumors
Read more →CATXUnassociated Document For Release
For Release : November 13, 2008 at 7:30AM EST Contact: Michael Mason (investors) Jonathan Hunt, CFO Brian Kennedy (media) 509 375 1202 Allen & Caron Inc jhunt@isoray.com 212 691 8087 michaelm@allencaron.com brian@allencaron.com First Quarter Results Washington - IsoRay
Read more →CATXUnassociated Document For Immediate Release
Immediate Release: November Inc. First Quarter Fiscal Year 2008 Results Washington - IsoRay Inc. (AMEX: ISR) a medical isotope company focusing on treatment of prostate and other malignant disease through use of its proprietary radioisotope technology, announced its financial
Read more →CATXUnassociated Document FOR IMMEDIATE RELEASE
Inc. ANNOUNCES COMPLETION OF WARRANT CALL Inc. ("IsoRay") (OTCBB Symbol: ISRY), the medical technology company focusing on innovative treatments for solid cancer tumors using its proprietary Cesium-131 initially in brachytherapy seeds, announced today that all warrants that we
Read more →CATXUnassociated Document IsoRay Incorporated (ISRY.OB) Presentation at the Roth Capital Partners New York Conference Call
Incorporated (ISRY.OB) at the Roth Capital Partners New York Conference Call Speaker, IsoRay Incorporated>> we ready to go? Thank you all for coming to this conference. I appreciate being here. I would like to have you make sure you look at this forward-looking statement, re
Read more →CATXISORAY ANNOUNCES PRELIMINARY FISCAL YEAR 2006 RESULTS AND PROJECTED FIRST QUARTER 2007 SALES REVENUES RICHLAND, Wash. - (BUSINESS WIRE)
ANNOUNCES PRELIMINARY FISCAL YEAR 2006 RESULTS AND PROJECTED FIRST QUARTER (BUSINESS WIRE) - Sept. 6, 2006 - ISRY), a medical isotope company focusing on brachytherapy solutions for prostate and other malignant tissue cancers through use of its proprietary Cesium-131 radioiso
Read more →CATXUnassociated Document IsoRay Announces 1st Round of Institutional Financing Led by MicroCapital LLC; Raising over $5 Million RICHLAND, Wash.--(BUSINESS WIRE)
Announces 1st Round of Institutional Financing Led by MicroCapital LLC; Raising Wash.--(BUSINESS WIRE)--Aug. 18, 2006--IsoRay, Inc. ("IsoRay") (OTCBB:ISRY), medical technology company focusing on innovative treatments of solid cancer tumors through use of its proprietary Cesiu
Read more →CATXUnassociated Document ISORAY ANNOUNCES RECORD SEED ORDERS AND RESULTING IMPACT ON CASH RESERVES; NEW DEBT FINANCING; AND PLANNED REDUCTION IN OUTSTANDING SHARES RICHLAND, WA - IsoRay, Inc. ( " IsoRay " ) (OTCBB Symbol: I
ANNOUNCES RECORD SEED ORDERS AND RESULTING IMPACT ON CASH RESERVES; NEW DEBT FINANCING; AND PLANNED REDUCTION IN OUTSTANDING SHARES Symbol: ISRY), a medical technology company focusing on innovative treatment prostate and other soft tissue cancer tumors through use of its prop
Read more →Competitive Position
How CATX ranks across every disease it competes inCompetitive Position is a premium feature
See how CATX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial